Lunai Bioworks Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LNAI research report →
About the company
Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."
- CEO
- David H. Weinstein
- IPO
- 2025
- Employees
- 29
- HQ
- Los Angeles, CA, US
Price Chart
- Market Cap
- $14.51M
- P/E
- -0.05
- P/S
- 692.79
- P/B
- -1.05
- EV/EBITDA
- -0.10
- Div Yield
- 0.00%
- Gross Margin
- -360.71%
- Op Margin
- -46991.97%
- Net Margin
- -612568.11%
- ROE
- 892.52%
- ROIC
- 120.87%
- Revenue
- $0 · 0.00%
- Net Income
- $-178,007,489 · -101.31%
- EPS
- $-86.24 · -18.46%
- Op Income
- $-18,546,573
- FCF YoY
- 28.68%
- 52W High
- $28.80
- 52W Low
- $1.21
- 50D MA
- $2.74
- 200D MA
- $5.95
- Beta
- 0.36
- Avg Volume
- 1.56M
Get TickerSpark's AI analysis on LNAI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our LNAI coverage
Recent articles, reports, and earnings notes.
No research on LNAI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LNAI report →Similar companies
Peers in the same neighborhood.